<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03184870</url>
  </required_header>
  <id_info>
    <org_study_id>CV202-103</org_study_id>
    <secondary_id>2017-001725-40</secondary_id>
    <nct_id>NCT03184870</nct_id>
  </id_info>
  <brief_title>A Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Participants With Advanced Solid Tumors</brief_title>
  <official_title>A Phase 1b/2 Study of BMS-813160 in Combination With Chemotherapy or Nivolumab in Patients With Advanced Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Bristol-Myers Squibb</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Bristol-Myers Squibb</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to evaluate the safety profile, tolerability, drug levels, drug&#xD;
      effects, and preliminary efficacy of BMS-813160 alone or in combination with either&#xD;
      chemotherapy or nivolumab or chemotherapy plus nivolumab in participants with metastatic&#xD;
      colorectal and pancreatic cancers.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">August 8, 2017</start_date>
  <completion_date type="Anticipated">February 28, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 27, 2023</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Incidence of Adverse events (AEs)</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Part 1 only</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Serious adverse events (SAEs)</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Part 1 only</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of AEs meeting protocol-defined Dose Limiting Toxicity (DLT) criteria</measure>
    <time_frame>Approximately 6 months</time_frame>
    <description>Part 1 only</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of AEs leading to discontinuation</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Part 1 only</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of Death</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Part 1 only</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory results: Hematology tests</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Part 1 only</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory results: Clinical Chemistry tests</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Part 1 only</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory results: Urinalysis tests</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Part 1 only</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in electrocardiogram (ECG) parameters: PR interval</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Part 1 only PR interval: The time from the onset of the P wave to the start of the QRS complex</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QRS interval</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Part 1 only QRS interval: A combination of the Q wave, R wave and S wave, the &quot;QRS complex&quot; represents ventricular depolarization</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QT interval</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Part 1 only QT interval: Measured from the beginning of the QRS complex to the end of the T wave</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QTcF interval</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Part 1 only QTcF interval: Corrected QT interval using Fridericia's formula (QTcF)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in vital signs: Body temperature</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Part 1 only</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in vital signs: Respiratory rate</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Part 1 only</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in vital signs: Pulse oximetry</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Part 1 only</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in vital signs: Blood pressure</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Part 1 only</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence of clinically significant changes in vital signs: Heart rate</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Part 1 only</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Decrease in regulatory T cells (Treg) or tumor-associated macrophage (TAM) in tumor samples</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Part 1 only</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Overall response rate (ORR) as assessed by investigator using Response Evaluation Criteria in Solid Tumors (RECIST) v1.1</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Part 2 only</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Median duration of response (DOR)</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Part 2 only</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression free survival (PFS) rate</measure>
    <time_frame>At 24 weeks</time_frame>
    <description>Part 2 only</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall response rate (ORR)</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Part 1 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median duration of response (DOR)</measure>
    <time_frame>Approximately 2 years</time_frame>
    <description>Part 1 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression free survival (PFS) rate</measure>
    <time_frame>At 24 weeks</time_frame>
    <description>Part 1 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Maximum observed plasma concentration (Cmax)</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Part 1 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time of maximum observed plasma concentration (Tmax)</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Part 1 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Trough observed plasma concentration (Ctrough)</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Part 1 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Observed plasma concentration at 24 hours post dose (C24)</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Part 1 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve from time 0 to 8 hours postdose [AUC(0-8)]</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Part 1 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area under the concentration-time curve from time 0 to 24 hours post dose [AUC(0-24)]</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Part 1 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Apparent total body clearance (CLT/F)</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Part 1 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Accumulation index, calculated based on ratio of AUC(0-24) and Cmax at steady state to after the first dose (AI)</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Part 1 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Renal clearance (CLR)</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Part 1 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent urinary recovery over 24 hours corrected for molecular weight (%UR)</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Part 1 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of metabolite Cmax to parent Cmax, corrected for molecular (MR_Cmax)</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Part 1 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Ratio of metabolite AUC(0-24) to parent AUC(0-24), corrected for molecular weight [MR_AUC(0-24)]</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Part 1 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Frequency of positive anti-drug antibody (ADA) to nivolumab during combination therapy</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Part 1 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Adverse events (AEs)</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Part 2 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Serious adverse events (SAEs)</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Part 2 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of AEs leading to discontinuation</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Part 2 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Death</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Part 2 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of AEs meeting protocol-defined Dose Limiting Toxicity (DLT) criteria</measure>
    <time_frame>Approximately 6 months</time_frame>
    <description>Part 2 Cohort 3b only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory results: Hematology tests</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Part 2 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory results: Clinical Chemistry tests</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Part 2 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in clinical laboratory results: Urinalysis tests</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Part 2 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in vital signs: Body temperature</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Part 2 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in vital signs: Respiratory rate</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Part 2 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in vital signs: Pulse oximetry</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Part 2 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in vital signs: Blood pressure</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Part 2 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in vital signs: Heart rate</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Part 2 only</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in electrocardiogram (ECG) parameters: PR interval</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Part 2 only PR interval: The time from the onset of the P wave to the start of the QRS complex</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QRS interval</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Part 2 only QRS interval: A combination of the Q wave, R wave and S wave, the &quot;QRS complex&quot; represents ventricular depolarization</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QT interval</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Part 2 only QT interval: Measured from the beginning of the QRS complex to the end of the T wave</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of clinically significant changes in electrocardiogram (ECG) parameters: QTcF interval</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Part 2 only QTcF interval: Corrected QT interval using Fridericia's formula (QTcF)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Decrease in regulatory T cells (Treg) &amp; tumor-associated macrophages (TAM) in tumor samples</measure>
    <time_frame>Approximately 4 years</time_frame>
    <description>Part 2 only</description>
  </secondary_outcome>
  <number_of_arms>13</number_of_arms>
  <enrollment type="Actual">332</enrollment>
  <condition>Colorectal Cancer</condition>
  <condition>Pancreatic Cancer</condition>
  <arm_group>
    <arm_group_label>Part 1 Arm A [First-line (1L) Colorectal]: BMS-813160 followed by BMS-813160 + FOLFIRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>FOLFIRI: FOL (folinic acid [leucovorin]) F (fluorouracil [5-fluorouracil]) IRI (irinotecan [CAMPTOSAR])</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Arm B [1L Pancreatic]: BMS-813160 followed by BMS-813160 + Gemcitabine/Nab-paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1 Arm C [2L Pancreatic &amp; 2/3L Colorectal MSS]: BMS-813160 followed by BMS-813160 + Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>2L: Second-line 2/3L: Second/third-line MSS: Microsatellite stable</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Arm A Cohort 1a [2L Colorectal]: BMS-813160 + FOLFIRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Arm A Cohort 1b [2L Colorectal]: BMS-813160 + FOLFIRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Arm A Cohort 1c [2L Colorectal]: FOLFIRI</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Arm B Cohort 3a [1L Pancreatic]: BMS-813160 + Gemcitabine/Nab-paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Arm B Cohort 3b [1L Pancreatic]: BMS-813160 + Nivolumab + Gemcitabine/Nab-paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Arm B Cohort 3c [1L Pancreatic]: Gemcitabine/Nab-paclitaxel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Arm C Cohort 4 [2L Pancreatic]: BMS-813160 + Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Arm C Cohort 5 [2/3L Colorectal MSS]: BMS-813160 + Nivolumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Arm D Cohort 7 [2L Pancreatic]: BMS-813160 Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 Arm D Cohort 8 [2/3L Colorectal MSS]: BMS-813160 Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BMS-813160</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part 1 Arm A [First-line (1L) Colorectal]: BMS-813160 followed by BMS-813160 + FOLFIRI</arm_group_label>
    <arm_group_label>Part 1 Arm B [1L Pancreatic]: BMS-813160 followed by BMS-813160 + Gemcitabine/Nab-paclitaxel</arm_group_label>
    <arm_group_label>Part 1 Arm C [2L Pancreatic &amp; 2/3L Colorectal MSS]: BMS-813160 followed by BMS-813160 + Nivolumab</arm_group_label>
    <arm_group_label>Part 2 Arm A Cohort 1a [2L Colorectal]: BMS-813160 + FOLFIRI</arm_group_label>
    <arm_group_label>Part 2 Arm A Cohort 1b [2L Colorectal]: BMS-813160 + FOLFIRI</arm_group_label>
    <arm_group_label>Part 2 Arm B Cohort 3a [1L Pancreatic]: BMS-813160 + Gemcitabine/Nab-paclitaxel</arm_group_label>
    <arm_group_label>Part 2 Arm B Cohort 3b [1L Pancreatic]: BMS-813160 + Nivolumab + Gemcitabine/Nab-paclitaxel</arm_group_label>
    <arm_group_label>Part 2 Arm C Cohort 4 [2L Pancreatic]: BMS-813160 + Nivolumab</arm_group_label>
    <arm_group_label>Part 2 Arm C Cohort 5 [2/3L Colorectal MSS]: BMS-813160 + Nivolumab</arm_group_label>
    <arm_group_label>Part 2 Arm D Cohort 7 [2L Pancreatic]: BMS-813160 Monotherapy</arm_group_label>
    <arm_group_label>Part 2 Arm D Cohort 8 [2/3L Colorectal MSS]: BMS-813160 Monotherapy</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Nivolumab</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part 1 Arm C [2L Pancreatic &amp; 2/3L Colorectal MSS]: BMS-813160 followed by BMS-813160 + Nivolumab</arm_group_label>
    <arm_group_label>Part 2 Arm B Cohort 3b [1L Pancreatic]: BMS-813160 + Nivolumab + Gemcitabine/Nab-paclitaxel</arm_group_label>
    <arm_group_label>Part 2 Arm C Cohort 4 [2L Pancreatic]: BMS-813160 + Nivolumab</arm_group_label>
    <arm_group_label>Part 2 Arm C Cohort 5 [2/3L Colorectal MSS]: BMS-813160 + Nivolumab</arm_group_label>
    <other_name>Opdivo</other_name>
    <other_name>BMS-936558</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part 1 Arm B [1L Pancreatic]: BMS-813160 followed by BMS-813160 + Gemcitabine/Nab-paclitaxel</arm_group_label>
    <arm_group_label>Part 2 Arm B Cohort 3a [1L Pancreatic]: BMS-813160 + Gemcitabine/Nab-paclitaxel</arm_group_label>
    <arm_group_label>Part 2 Arm B Cohort 3b [1L Pancreatic]: BMS-813160 + Nivolumab + Gemcitabine/Nab-paclitaxel</arm_group_label>
    <arm_group_label>Part 2 Arm B Cohort 3c [1L Pancreatic]: Gemcitabine/Nab-paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part 1 Arm B [1L Pancreatic]: BMS-813160 followed by BMS-813160 + Gemcitabine/Nab-paclitaxel</arm_group_label>
    <arm_group_label>Part 2 Arm B Cohort 3a [1L Pancreatic]: BMS-813160 + Gemcitabine/Nab-paclitaxel</arm_group_label>
    <arm_group_label>Part 2 Arm B Cohort 3b [1L Pancreatic]: BMS-813160 + Nivolumab + Gemcitabine/Nab-paclitaxel</arm_group_label>
    <arm_group_label>Part 2 Arm B Cohort 3c [1L Pancreatic]: Gemcitabine/Nab-paclitaxel</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>5-fluorouracil (5-FU)</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part 1 Arm A [First-line (1L) Colorectal]: BMS-813160 followed by BMS-813160 + FOLFIRI</arm_group_label>
    <arm_group_label>Part 2 Arm A Cohort 1a [2L Colorectal]: BMS-813160 + FOLFIRI</arm_group_label>
    <arm_group_label>Part 2 Arm A Cohort 1b [2L Colorectal]: BMS-813160 + FOLFIRI</arm_group_label>
    <arm_group_label>Part 2 Arm A Cohort 1c [2L Colorectal]: FOLFIRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Leucovorin</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part 1 Arm A [First-line (1L) Colorectal]: BMS-813160 followed by BMS-813160 + FOLFIRI</arm_group_label>
    <arm_group_label>Part 2 Arm A Cohort 1a [2L Colorectal]: BMS-813160 + FOLFIRI</arm_group_label>
    <arm_group_label>Part 2 Arm A Cohort 1b [2L Colorectal]: BMS-813160 + FOLFIRI</arm_group_label>
    <arm_group_label>Part 2 Arm A Cohort 1c [2L Colorectal]: FOLFIRI</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Irinotecan</intervention_name>
    <description>Specified dose on specified days</description>
    <arm_group_label>Part 1 Arm A [First-line (1L) Colorectal]: BMS-813160 followed by BMS-813160 + FOLFIRI</arm_group_label>
    <arm_group_label>Part 2 Arm A Cohort 1a [2L Colorectal]: BMS-813160 + FOLFIRI</arm_group_label>
    <arm_group_label>Part 2 Arm A Cohort 1b [2L Colorectal]: BMS-813160 + FOLFIRI</arm_group_label>
    <arm_group_label>Part 2 Arm A Cohort 1c [2L Colorectal]: FOLFIRI</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        For more information regarding Bristol-Myers Squibb Clinical Trial participation, please&#xD;
        visit www.BMSStudyConnect.com&#xD;
&#xD;
        Inclusion Criteria:&#xD;
&#xD;
          -  Must have metastatic colorectal or pancreatic cancer&#xD;
&#xD;
          -  Eastern Cooperative Oncology Group (ECOG) performance status of ≤1&#xD;
&#xD;
          -  Ability to swallow pills or capsules&#xD;
&#xD;
          -  Required to undergo mandatory pre and on-treatment biopsies&#xD;
&#xD;
          -  Adequate marrow function&#xD;
&#xD;
          -  Adequate other organ functions&#xD;
&#xD;
          -  Ability to comply with study visits, treatment, procedures, pharmacokinetic (PK) and&#xD;
             pharmacodynamic (PD) sample collection, and required study follow-up&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Histology other than adenocarcinoma (neuroendocrine or acinar cell)&#xD;
&#xD;
          -  Suspected, known, or central nervous system (CNS) metastases (Imaging required only if&#xD;
             participants are symptomatic)&#xD;
&#xD;
          -  Active, known or suspected autoimmune disease&#xD;
&#xD;
          -  Condition requiring systemic treatment with either corticosteroids (&gt; 10 mg daily&#xD;
             prednisone equivalents) or other immunosuppressive medications within 14 days of study&#xD;
             treatment administration&#xD;
&#xD;
          -  Interstitial lung disease that is symptomatic or may interfere with the detection or&#xD;
             management of suspected treatment-related pulmonary toxicity&#xD;
&#xD;
          -  Prior treatment with cysteine-cysteine chemokine receptor 2 (CCR2) and/or&#xD;
             cysteine-cysteine chemokine receptor 5 (CCR5) inhibitors, programmed death-1 receptor&#xD;
             (PD-1), programmed death-ligand 1 [PD(L)-1] or cytotoxic T-lymphocyte antigen-4&#xD;
             (CTLA-4) antibodies&#xD;
&#xD;
          -  History of allergy to study treatments or any of its components of the study arm that&#xD;
             participant is enrolling&#xD;
&#xD;
        Other protocol-defined inclusion/exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Bristol-Myers Squibb</last_name>
    <role>Study Director</role>
    <affiliation>Bristol-Myers Squibb</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University Of Alabama At Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35294-3300</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - PPDS</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85054</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>USC Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Usc/Norris Comprehensive Cancer Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90033</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Uc Irvine Medical Center</name>
      <address>
        <city>Orange</city>
        <state>California</state>
        <zip>92868</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Colorado</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Georgetown University Medical Center</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20007</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists - South</name>
      <address>
        <city>Fort Myers</city>
        <state>Florida</state>
        <zip>33901</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists - North</name>
      <address>
        <city>Saint Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Massachusetts General Hospital</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - PPDS</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905-0001</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hattiesburg Clinic</name>
      <address>
        <city>Hattiesburg</city>
        <state>Mississippi</state>
        <zip>39401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Washington University School of Medicine</name>
      <address>
        <city>Saint Louis</city>
        <state>Missouri</state>
        <zip>63110</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hackensack University Medical Center</name>
      <address>
        <city>Hackensack</city>
        <state>New Jersey</state>
        <zip>07601</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Sloan Kettering Nassau</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10065</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Rochester</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14642</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Levine Cancer Institute- Atrium Health</name>
      <address>
        <city>Charlotte</city>
        <state>North Carolina</state>
        <zip>28204</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Hospitals Cleveland Medical Center</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106-5055</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cleveland Clinic Foundation</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lehigh Valley Health Network</name>
      <address>
        <city>Allentown</city>
        <state>Pennsylvania</state>
        <zip>18103</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Thomas Jefferson University</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19107</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical University of South Carolina Hollings Cancer Center</name>
      <address>
        <city>Charleston</city>
        <state>South Carolina</state>
        <zip>29425</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tennessee Oncology PLLC</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University Med Ctr</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Huntsman Cancer Institute</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84112</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Virginia</name>
      <address>
        <city>Charlottesville</city>
        <state>Virginia</state>
        <zip>22908</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cabrini Hospital</name>
      <address>
        <city>Clayton</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Bruxelles</city>
        <zip>1200</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Edegem</city>
        <zip>2650</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Leuven</city>
        <zip>3000</zip>
        <country>Belgium</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cross Cancer Institute</name>
      <address>
        <city>Edmonton</city>
        <state>Alberta</state>
        <zip>T6G 1Z2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Local Institution</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <zip>M5G 1X6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Carl Gustav Carus</name>
      <address>
        <city>Dresden</city>
        <zip>01307</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Del Mar</name>
      <address>
        <city>Barcelona</city>
        <zip>08003</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Univ. La Paz</name>
      <address>
        <city>Madrid</city>
        <zip>28046</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hosp. Univ. Puerta De Hierro</name>
      <address>
        <city>Majadahonda - Madrid</city>
        <zip>28222</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Australia</country>
    <country>Belgium</country>
    <country>Canada</country>
    <country>Germany</country>
    <country>Spain</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>France</country>
  </removed_countries>
  <link>
    <url>https://www.bms.com/researchers-and-partners/clinical-trials-and-research.html</url>
    <description>BMS Clinical Trial Information</description>
  </link>
  <link>
    <url>https://www.bmsstudyconnect.com/s/US/English/USenHome</url>
    <description>BMS Clinical Trial Patient Recruiting</description>
  </link>
  <link>
    <url>https://www.fda.gov/Safety/MedWatch/SafetyInformation/default.htm</url>
    <description>FDA Safety Alerts and Recalls</description>
  </link>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>June 9, 2017</study_first_submitted>
  <study_first_submitted_qc>June 9, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">June 14, 2017</study_first_posted>
  <last_update_submitted>April 16, 2021</last_update_submitted>
  <last_update_submitted_qc>April 16, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Leucovorin</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Fluorouracil</mesh_term>
    <mesh_term>Nivolumab</mesh_term>
    <mesh_term>Irinotecan</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

